House Bill Proposes OTA Authority and Innovation Office for VA Procurement
Bipartisan House legislation aims to grant the Department of Veterans Affairs Other Transaction Authority and establish a dedicated Office of Innovation. The bill includes $10 million for OT agreements to accelerate cutting-edge medical tools and dual-use health technologies to veterans.
Proposed legislation in the House of Representatives aims to fundamentally overhaul how the Department of Veterans Affairs (VA) acquires, tests, and deploys emerging medical technologies. The newly introduced INNOVATE Act seeks to establish a dedicated Office of Innovation alongside granting the agency Other Transaction Authority (OTA)—a flexible procurement instrument traditionally favored by the Department of Defense (DoD) to bypass traditional Federal Acquisition Regulation (FAR) constraints. Under the proposed statutory framework, the VA would gain authority to execute OT deals valued at up to $10 million per transaction, supported by a specialized flexible fund structured specifically to accelerate prototyping, field testing, and transitioning novel clinical tools and health technologies to veteran care facilities.
For defense acquisition officials and federal health leadership, expanding OTA mechanisms to the VA represents a strategic alignment between military readiness and veteran healthcare infrastructure. Historically, rigid procurement cycles have severely delayed the operational adoption of advanced commercial capabilities, such as AI-driven diagnostic software, advanced prosthetic systems, and real-time remote biometric monitoring. By leveraging OTA flexible contracting tools, the VA can eliminate systemic procurement lag, harmonizing its technology insertion pathways with ongoing defense health initiatives—including joint military health enterprise systems and specialized battlefield-to-veteran medical transitions managed by the Defense Health Agency.
For commercial contractors, technology startups, and traditional defense vendors, the legislation creates lucrative new acquisition pipelines outside the conventional DoD umbrella. Other Transaction agreements enable non-traditional defense contractors—who routinely avoid standard government procurement due to onerous cost-accounting standards and restrictive intellectual property rights—to enter into flexible collaborative arrangements directly with VA research units and clinicians. Industry partners that offer dual-use health capabilities, resilient mission operational technology, and specialized health software will find expanded opportunities to secure non-FAR seed funding and establish enterprise scale across the federal marketplace.
Looking forward, this bill establishes a major milestone for expanding non-FAR procurement frameworks into high-priority civilian agency missions. Government and industry procurement executives should anticipate a rising demand for specialized innovation consortia, dynamic prototyping models, and flexible commercial licensing agreements tailored for federal health networks. Strategic leaders in both the public and private defense sectors must proactively monitor this legislative trajectory to ensure their dual-use technology portfolios are properly positioned for swift contracting and scaling across both the VA and military health systems. (Source: ExecutiveGov)
Executive takeaway
Subscribe to receive signals like this — plus the executive analysis behind them.
Get the Signals